|1.||Thiemermann, Christoph: 7 articles (09/2008 - 03/2006)|
|2.||Cuzzocrea, Salvatore: 4 articles (01/2007 - 05/2006)|
|3.||Mazzon, Emanuela: 4 articles (01/2007 - 05/2006)|
|4.||Ge, Yan: 3 articles (06/2015 - 04/2012)|
|5.||Gong, Rujun: 3 articles (06/2015 - 04/2012)|
|6.||Crisafulli, Concetta: 3 articles (01/2007 - 07/2006)|
|7.||Di Paola, Rosanna: 3 articles (01/2007 - 07/2006)|
|8.||Muià, Carmelo: 3 articles (01/2007 - 07/2006)|
|9.||Collin, Marika: 3 articles (07/2006 - 03/2006)|
|10.||Bao, Hui: 2 articles (06/2015 - 02/2015)|
04/01/2015 - "Our study provides a new insight on the beneficial effects of GSK-3β inhibition on systemic inflammation and further elucidates the mechanism and pathway crosstalks by which TDZD-8 reduces the multiple organ injury elicited by thermal injury. "
01/01/2010 - "Treatment with TDZD-8 improved gas exchange (arterial pO2), but I/R-induced inflammation (plasma interleukin-6, leukocyte invasion) was not affected. "
03/01/2006 - "Administration of the GSK-3beta inhibitor TDZD-8 (0.1, 0.33 or 1.0 mg kg-1, s.c., b.i.d., for 3 days) caused a dose-dependent reduction in the colonic inflammation induced by intracolonic TNBS assessed after 3 days, both as the area of macroscopic involvement and as a score using 0-10 scale. "
07/01/2007 - "Taken together, these results clearly demonstrate treatment with the GSK-3beta inhibitor TDZD-8 reduces the development of lung injury and inflammation induced by BLM in mice."
11/01/2006 - "Administration of TDZD-8 (1, 3 or 10 mg kg(-1), i.p.), 30 min prior to injection of carrageenan, caused a dose-dependent reduction in all the parameters of inflammation measured. "
01/01/2010 - "The specific non-competitive inhibitor of GSK-3β, TDZD-8, was injected (3 mg/kg, vehicle in controls) 5 min before the left lung hilum was occluded for 60 min. Animals in the ischemia group underwent the same treatment, but without administration of TDZD-8. "
09/01/2008 - "The selective GSK-3beta inhibitor, 4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione (TDZD-8), was administered before and after ischemia or during reperfusion alone to assess its potential as prophylactic or therapeutic strategy. "
02/01/2010 - "In rats, TDZD-8 inhibited ischemia-induced activation of GSK3beta, Bax, and caspase 3; ameliorated tubular and epithelial cell damage; and significantly protected renal function. "
08/01/2015 - "Pharmacological inhibition of GSK3 using TDZD-8 starting before or after ischemia-reperfusion significantly suppressed renal fibrosis by reducing the myofibroblast population, collagen-1 and fibronectin deposition, inflammatory cytokines, and macrophage infiltration. "
04/01/2015 - "In the liver ischemia-reperfusion model, TDZD-8 and insulin were administered at 5 mg/kg (i.v.) and 1.4 IU/kg (i.v.), respectively, 30 min before induction of ischemia and led to the significant reduction of the serum concentration of aspartate aminotransferase, alanine aminotransferase, γ-glutamyltransferase, and lactate dehydrogenase. "
06/01/2015 - "In vivo, lithium or TDZD-8 therapy improved podocyte injury and proteinuria in mice treated with LPS or ADR, concomitant with the suppression of podocytopathic mediators, but retained Bcl-xL in glomerulus. "
02/01/2015 - "TDZD-8 therapy prominently ameliorated the proteinuria and glomerular sclerosis in mice with adriamycin nephropathy; this was associated with a correction of GSK3β overactivity in the glomerulus and attenuation of podocyte injuries, including foot process effacement and podocyte death. "
02/01/2013 - "Remifentanil induced significant postoperative hyperalgesia, as indicated by increased paw withdrawal latencies and thresholds to thermal and mechanical stimulation, which were markedly improved by pretreatment with TDZD-8. "
01/01/2013 - "GSK-3β inhibitor TDZD-8 significantly attenuated remifentanil-induced mechanical and thermal hyperalgesia from 2 h to 48 h after infusion, and this was associated with reversal of up-regulated NR1 and NR2B subunits in both membrane fraction and total lysate. "
01/01/2013 - "We firstly investigated the effects of TDZD-8, a selective GSK-3β inhibitor, on thermal and mechanical hyperalgesia using a rat model of remifentanil-induced hyperalgesia. "
02/01/2013 - "Furthermore, we investigated the effects of TDZD-8, a selective GSK-3β inhibitor, on remifentanil-induced postoperative hyperalgesia and NMDA receptor subunits trafficking. "
|1.||glycogen synthase kinase 3 beta
|2.||Glycogen Synthase Kinases
|3.||Interleukin-6 (Interleukin 6)
|4.||Cyclooxygenase 2 (Cyclooxygenase-2)
|8.||L-Lactate Dehydrogenase (Lactate Dehydrogenase)
|10.||Aspartate Aminotransferases (Aspartate Transaminase)
|1.||Heterologous Transplantation (Xenotransplantation)